

Cancer Risks

Strategies for Elimination

Edited by
Peter Bannasch

With 34 Figures

Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo

Prof. Dr. PETER BANNASCH
Institut für Experimentelle Pathologie
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-6900 Heidelberg

The publication of this book was supported by the Arbeitsgemeinschaft für
Grossforschungseinrichtungen (AGF).

Institutions participating in the AGF-Koordinierungsausschuß Krebsforschung

DKFZ Deutsches Krebsforschungszentrum Heidelberg

GBF Gesellschaft für Biotechnologische Forschung Braunschweig

GSF Gesellschaft für Strahlen- und Umweltforschung Neuherberg

KFA Kernforschungsanlage Jülich

KfK Kernforschungszentrum Karlsruhe

ISBN 3-540-17465-6 Springer-Verlag Berlin Heidelberg New York

ISBN 0-387-17465-6 Springer-Verlag New York Berlin Heidelberg

Library of Congress Cataloging-in-Publication Data. Cancer risks. Includes bibliographies and index.
1. Cancer – Prevention. 2. Carcinogens. 3. Carcinogenesis. 4. Health risk assessment. I. Bannasch,
Peter. [DNLM: 1. Carcinogens – toxicity. 2. Neoplasms – prevention & control. 3. Oncogenic
Viruses – pathogenicity. QZ 202 C21564]
RC268.C3676 1987 616.99'4052 87-4350
ISBN 0-387-17465-6 (U.S.)

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is
concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broad-
casting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this
publication or parts thereof is only permitted under the provisions of the German Copyright Law of
September 9, 1965, in its version of June 24, 1985, and a copyright fee must always be paid. Violations
fall under the prosecution act of the German Copyright Law.

© Springer-Verlag Berlin Heidelberg 1987

Printed in Germany

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence
of a specific statement, that such names are exempt from the relevant protective laws and regulations
and therefore free for general use.

Product liability: The publisher can give no guarantee for information about drug dosage and applica-
tion thereof contained in this book. In every individual case the respective user must check its ac-
curacy by consulting other pharmaceutical literature.

Typesetting, printing and bookbinding by

Petersche Druckerei GmbH & Co. Offset KG, Rothenburg ob der Tauber
121/3130-543210



Contents

Session 1

General Aspects

Chairman: F. VOGEL

Genetic Predisposition for Cancer Risks in Man

D. G. HARNDEN 3

The Role of Epidemiology in the Detection and Reduction of Cancer Risks

R. DOLL 14

Summary of Discussion: Session 1

L. ARAB-KOHLMEIER 24

Session 2

Chemical Carcinogens: Risk Assessment

Chairman: D. NEUBERT

Assessment of Cancer Risk from Chemicals

D. HENSCHLER 27

Validity of Short-Term Tests to Detect Carcinogenic Chemicals

H. GREIM, U. ANDRAE, W. GÖGGMANN, L. SCHWARZ,
and K. H. SUMMER (With 5 Figures) 33

Preneoplastic Lesions as Indicators of the Carcinogenic Risk Caused by Chemicals

P. BANNASCH, H. ENZMANN, and H. ZERBAN (With 6 Figures) 47

Carcinogenic Risk Assessment: Are Animals Good Surrogates for Man?

I. F. H. PURCHASE 65

Summary of Discussion: Session 2

R. BASS 80

Session 3

Chemical Carcinogens: Primary Prevention

Chairman: D. SCHMÄHL

Possibilities of Primary Prevention Against Chemical Carcinogens R. PREUSSMANN (With 3 Figures)	87
Primary Prevention Against Occupational Carcinogens P. J. LANDRIGAN and I. J. SELIKOFF	94
Chemical Carcinogens in Tobacco D. HOFFMANN, E. L. WYNDER, S. S. HECHT, K. D. BRUNNEMANN, E. J. LA VOIE, and N. J. HALEY (With 4 Figures)	101
Primary Prevention of Tobacco-Related Cancer E. L. WYNDER and M. A. ORLANDI (With 6 Figures)	114
Summary of Discussion: Session 3 H.-G. NEUMANN	133

Session 4

Physical Carcinogens

Chairman: W. GÖSSNER

Cancer Risk from Ultraviolet Radiation H. IPPEN	137
Assessment of Cancer Risks Due to Ionizing Radiations A. M. KELLERER (With 1 Figure)	143
Cancer Risk from Environmental Radioactivity W. JACOBI (With 5 Figures)	154
Summary of Discussion: Session 4 E. W. HAHN	166

Session 5

Oncogenic Viruses

Chairman: E. WECKER

Viruses in Human Tumors H. ZUR HAUSEN (With 1 Figure)	171
Strategies in the Prevention of Infections by Oncogenic Viruses F. DEINHARDT (With 3 Figures)	181

Summary of Discussion: Session 5

G. HUNSMANN 190

Summary of Round Table Discussion on Strategies
Against Tobacco Cancer

G. EISENBRAND 192

Subject Index 195

List of Contributors

- ANDRAE, ULRICH, Institut für Toxikologie der Gesellschaft für Strahlen- und Umweltforschung, D-8042 Neuherberg, FRG
- ARAB-KOHLMEIER, LENORE, Bundesgesundheitsamt, Institut für Sozialmedizin und Epidemiologie, Postfach 330013, D-1000 Berlin 33, FRG
- BANNASCH, PETER, Institut für Experimentelle Pathologie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG
- BASS, ROLF, Bundesgesundheitsamt, Thielallee 88-92, D-1000 Berlin 33, FRG
- BRUNNEMANN, KLAUS D., Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, NY 10595, U.S.A.
- DEINHARDT, FRIEDRICH, Max von Pettenkofer Institut für Hygiene und Medizinische Mikrobiologie der Ludwig-Maximilians-Universität München, Pettenkoferstr. 9, D-8000 München 2, FRG
- DOLL, RICHARD, SIR, Imperial Cancer Research Fund, Cancer Epidemiology Unit, Radcliffe Infirmary, Oxford OX2 6HE, U.K.
- EISENBRAND, GERHARD, Lebensmittelchemie und Umwelttoxikologie der Universität Kaiserslautern, Erwin-Schrödinger-Str., D-6750 Kaiserslautern, FRG
- ENZMANN, HARALD, Institut für Experimentelle Pathologie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG
- GÖGGELMANN, WALTRAUD, Institut für Toxikologie der Gesellschaft für Strahlen- und Umweltforschung, D-8042 Neuherberg, FRG
- GREIM, HELMUT, Institut für Toxikologie der Gesellschaft für Strahlen- und Umweltforschung, D-8042 Neuherberg, FRG
- HAHN, ERIC W., Institut für Nuklearmedizin, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG
- HALEY, NANCY J., Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, NY 10595, U.S.A.

- HARDEN, DAVID G., The Paterson Laboratories, Christie Hospital and Holt Radium Institute, Wilmslow Road, Manchester M20 9BX, U.K.
- HAUSEN ZUR, HARALD, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG
- HECHT, STEPHEN S., Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, NY 10595, U.S.A.
- HENSCHLER, DIETER, Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Landstr. 9, D-8700 Würzburg, FRG
- HOFFMANN, DIETRICH, Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, NY 10595, U.S.A.
- HUNSMANN, GERHARD, Abteilung für Virologie und Immunologie, Deutsches Primatenzentrum, Kellnerweg 4, D-3400 Göttingen, FRG
- IPPEN, HELMUT, Abt. Dermatologie und Venerologie I, Universitäts-Hautklinik, von Siebold-Str. 3, D-3400 Göttingen, FRG
- JAKOBI, WOLFGANG, GSF Neuherberg, Institut für Strahlenschutz, Ingolstädter Landstr. 1, D-8042 Neuherberg, FRG
- KELLERER, ALBRECHT M., Institut für Medizinische Strahlenkunde, Universität Würzburg, Versbacher Landstr. 5, D-8700 Würzburg, FRG
- LANDRIGAN, PHILIPP J., Environmental Sciences Laboratory, Mount Sinai School of Medicine of The City of New York, 10 East 102nd Street, New York, NY 10029, U.S.A.
- LAVOIE, EDMOND J., Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, NY 10595, U.S.A.
- NEUMANN, HANS-GÜNTER, Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Landstr. 9, D-8700 Würzburg, FRG
- ORLANDI, MARIO A., American Health Foundation, 320 East 43rd Street, New York, NY 10017, U.S.A.
- PREUSSMANN, RUDOLF, Institut für Toxikologie und Chemotherapie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG
- PURCHASE, IAIN F. H., Central Toxicology Laboratory, Imperial Chemical Institutes PLC., Alderley Park near Macclesfield, Chesire SK10 4TJ, U.K.
- SCHWARZ, LESLIE, Institut für Toxikologie der Gesellschaft für Strahlen- und Umweltforschung, D-8042 Neuherberg, FRG
- SELIKOFF, IRVING J., Environmental Sciences Laboratory, Mount Sinai School of Medicine of The City University of New York, 10 East 102nd Street, New York, NY 10029, U.S.A.

SUMMER, KARL-HEINZ, Institut für Toxikologie der Gesellschaft für Strahlen- und Umweltforschung, D-8042 Neuherberg, FRG

WYNDER, ERNEST L., American Health Foundation, Mahoney Institute Maintenance, 320 East 43rd Street, New York, NY 10017, U.S.A.

ZERBAN, HEIDE, Institut für Experimentelle Pathologie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-6900 Heidelberg, FRG

Assessment of Cancer Risks Due to Ionizing Radiations

A. M. KELLERER

Introduction

The enduring controversy on nuclear energy and the recent reactor accident have made ionizing radiation one of the most widely discussed tumor-inducing agents, although compared with major contributors, such as tobacco, its role appears to be minor. There is also little doubt that ionizing radiation is probably the one carcinogen which has been most extensively studied. X-rays were discovered in 1895, and 17 years passed before physicists began to understand their nature. But it took merely a few weeks before the first skin lesions were seen, and only 7 years before an X-ray induced skin cancer was recognized (Frieben 1902). In 1911 when Max von Laue obtained the first X-ray diffraction patterns in Munich, von Jagie et al. (1911) in Berlin reported a cluster of five leukemias in radiologists. The lesson was learned slowly. The hands of radiologists were less widely used as routine test objects for focusing the X-ray equipment, but scattered radiation or even the primary beam were not generally avoided, and before long leukemia became the professional affliction of radiologists.

A first dose limit was set in 1921 in terms of an observable skin reaction, a level 100 times the present limits. In 1928 the International Commission for Radiological Protection (ICRP) was founded, just 1 year after H. J. Muller (1927) had shown the mutagenic potential of X-rays and the apparent absence of a threshold. At the time the limit for radiation workers was set at 6 roentgen per month, a dose roughly comparable to 0.06 Sv per month, in today's units. The value was about 15 times higher than present limits, and adherence to the regulations may then have been far below present standards. The prevailing philosophy was still, that tumors could be induced by radiation only after a persistent accumulation of high radiation doses.

As a little-known aside of some historical interest one may note that Giachino Failla, the distinguished radiologist and physicist, had recommended at the time a "tolerance dose rate" of 0.6 roentgen per month, a value nearly equal to today's limit. The proposal was based on animal and human data (Failla 1932). He "had at the hospital a canary which has been continuously (day and night) in a beam of X-rays for about five months. . . . In this time the bird has received about 6000 roentgen of hard X-rays without apparent deleterious effects." However, Failla was also aware of effects that may develop later, hence the need for an epidemiological study – also of modest proportions. Three of his technicians were in charge of administering the 4 g radium pack at Memorial Hospital. Averaging over several years a dose of roughly 0.6 roentgen per month, they exhibited no substantial depression of white blood counts and no degree of lowered vitality. Thus, the limit seemed appropriate.

Between 1920 and 1930, and even later, appalling misuses of X-rays – even their utilization to terminate pregnancies – were still common. Treatment of benign conditions with X-rays or radionuclides was fairly general, which led to a wide range of observations on radiation-induced tumors (UNSCEAR 1977; NAS/NRC 1980). Diagnostic application of X-rays and technical uses of radionuclides were other areas where little or no concern was given to radiation protection.

Former Misuses of Radionuclides

The tragic heritage of the misuses of ionizing radiation in three main fields of application can be seen in the fate of patients treated with the short-lived radium-224, of patients (mostly soldiers) subjected to angiography with the α -emitting contrast medium thorotrast, and in industrial workers (mostly young women) who incorporated large amounts of radium-226 and radium-228 when they painted luminous dials. A brief consideration of these experiences may help to put some of the present problems and anxieties into perspective.

The last-named example concerns the most disastrous industrial misuse of a radionuclide. There were nearly 2000 workers, in the United States alone, who painted luminous watch dials with the long-lived radium-226. These workers, mostly young girls, were paid by the piece, and consequently they used the quickest method to sharpen the tips of the brushes. Employing their lips to sharpen the brushes they ingested large amounts of the radium paint. The high doses of incorporated radium led to numerous osteosarcomas and carcinomas of the paranasal sinuses or mastoids. Up to 1983, these tumors had contributed 12% of all deaths that have occurred in those whose radium intake has been measured. The Center of Human Radiobiology at Argonne National Laboratory has been in charge of the epidemiological study (Rundo et al. 1986); it has recently been reduced to a size which will make it nearly impossible to continue a valid follow-up of the fate of the dial painters. The resulting loss of singular medical and scientific information will be irreversible as well as indefensible.

The dentist of one of the dial painters first assumed red phosphorus to be a component of the luminous paint and blamed it for his patient's grave jaw damage. When this explanation failed, he continued to search for an explanation. Harrison Martland, whom he had consulted, focused his suspicion on radium-226. When this became known, he received an angry letter from Mme Curie; herself a victim of radiation, she called him a charlatan for failing to acknowledge that radiation can do no harm except at very large doses (Merril Eisenbud, personal communication). Although the letter has been lost, it remains a telling sign of the lack of appreciation of radiation risks in the first half of this century.

Decades later an equally tragic misuse of an α -emitting radionuclide occurred in Germany where, at a private clinic shortly after the Second World War, numerous children with bone tuberculosis were injected with large amounts of radium-224 and where the same treatment was given to adults with ankylosing spondylitis (Morbus Bechterew). The fate of the patients might never have become known, except for the actions of a young pediatrician who observed the treatment and spoke out against it. Heinz Spiess secured against the opposition of the director of the clinic the patient data and he has, jointly with Charles Mays, conducted one of the most important







studies of a group of patients subjected to the effects of ionizing radiations (Mays et al. 1986). Unlike the British ankylosing spondylitis patients who were treated with X-rays and developed, as Court Brown and Doll (1956) and Smith and Doll (1982) have demonstrated, an excess rate of leukemias and other tumors, the radium-224 patients incurred a large number of osteosarcomas. There were more than 50 osteosarcomas in the group of roughly 800 patients who were followed. Among the children with the largest doses, the rate of osteosarcomas was extremely high. Radium-224 has a short half-time of only 3.5 days, and the temporal pattern of the occurrence of osteosarcomas is, therefore, the undistorted response to irradiations fractionated over treatment periods of only several months. A maximum of the rate of osteosarcomas was found 5 to 10 years after the treatment, in later years the number of cases has declined. The quantitative analysis of the data has led to a linear-quadratic dose dependence with the risk estimate of $8.5 \cdot 10^{-3}$ per gray of mean skeletal dose (Chmelevsky et al. 1986). The study has been extended now to include various other types of radiation damage, including radiation-induced cataracts.

The observations on the radium-224 patients are directly relevant to a continuing medical practice. Treatment of ankylosing spondylitis with radium-224 is still practised in Germany, but far lower doses are given which amount to a mean skeletal dose of less than 1 gray. The osteosarcoma risk from this treatment would appear to be less than 1% according to the results of the Spiess study. The continued epidemiological investigation of the low dose treatment is consistent with this estimate (Wick et al. 1986). Despite the remaining hazard of osteosarcoma induction, there are valid arguments to defend the present-day radium-224 treatment of ankylosing spondylitis.

The deplorable consequences of another major misuse of a radionuclide are being studied in Heidelberg by von Kaick and his colleagues (1986). Thorotrast was probably the best contrast medium ever available for angiography. However, it contained thorium-232, an α -emitter of extremely long life time. Although numerous lives were saved by the use of thorotrast, it is by now inconceivable that thorotrast was still utilized up to and even beyond 1950. A number of scientists in different countries have studied, and are still studying, the effects of thorotrast which stays in the tissue and blood vessels of the patients, and which has caused a large number of liver tumors. For the remaining patients, liver tumors are now responsible for roughly half of all deaths.

Observation of the Atomic Bomb Survivors and the Estimation of Risk Coefficients

The main source of knowledge on radiation-induced tumors has been and continues to be the fate of the survivors of the atomic bombings. Studies have been performed during the past 40 years, first by the Atomic Bomb Casualty Commission (ABCC) and later by the Radiation Effects Research Foundation (RERF) in Hiroshima (see Yoshimoto et al. 1981; Ellett et al. 1985). The Life Span Study sample (LSS) contains about 60000 survivors of the bombing in Hiroshima and about 30000 survivors of the bombing in Nagasaki. When the bombs were used against Japan no radiation effects were foreseen, since those who would be highly exposed were expected not to survive the heat and the blast.



The diagrams of Fig. 1 show the positions of the survivors at the time of the bombing up to a distance of 2000 m from the hypocenters; they also show the extent of acute deaths at smaller distances and the number of cancer and leukemia deaths. Against expectation, and after merely a few years, leukemias appeared in excessive numbers among the survivors in Hiroshima and Nagasaki. The excess rates were so high that almost all leukemias among the highly exposed and about half of all leukemias recorded in the diagrams are due to the irradiation. These observations, the earlier data on the British ankylosing spondylitis patients (Court Brown and Doll 1956), and the leukemias in radiologists led E. B. Lewis to the hypothesis that leukemia could result from a radiation-induced mutation in a single blood-forming cell and to the assumption that the incidence of cancers might increase as a linear function of dose without threshold (Lewis 1957, 1963). At the time, this assumption was less controversial than it is nowadays, because it was still held that hereditary damage was the principle hazard of low doses of ionizing radiations.

Subsequent studies, mainly on the survivors of the atomic bombings and among the British ankylosing spondylitis patients, have provided a wide range of data on various tumors produced by ionizing radiations in man. For solid tumors, the relative increase of the spontaneous rates turned out to be much lower than for leukemia. But the total number of cases is sufficiently large to derive dose dependences for tumors of various organs. Although significant excesses have been seen only at doses of about 1 Gy or more, risk coefficients have been derived which are now applied to very small doses. Table 1 contains risk coefficients presented by ICRP (1977), and a few essential observations must be made.

First, the numerical values of the risk coefficients are such that the total risk for life-time cancer mortality exceeds the risk for hereditary damage. In fact, the comparison can only be valid if a dose dependence without threshold is assumed for radiation-induced tumors. The ICRP has made this assumption, and has made it the basis of its radiation protection philosophy.

In the present context it is interesting to note that hereditary damage due to ionizing radiation has never been demonstrated in man, not even in the descendants of the survivors from Hiroshima and Nagasaki. Great efforts have been made and are still being made to demonstrate the genetic effects. Plans are considered, at present, to supplement past work on protein analysis by an extensive program of DNA studies. That past efforts have failed to demonstrate genetic effects of the irradiation is due to the predominance of other factors which mask the small expected increments. It is, nevertheless, agreed that hereditary effects are caused by ionizing radiations and that they are produced without a threshold of dose. One can, furthermore, assume that the numerical estimates of the risk coefficients are of the right order of magnitude.

For radiation carcinogenesis the situation is reversed. There is a wealth of data, but the extrapolation to low doses remains a conjecture. The linear hypothesis can

Fig. 1. Coordinate plots (Yoshimoto et al. 1981) of the persons in the LSS sample who were within 2000 m of the hypocenters at the bombing of Hiroshima (*left column*) and Nagasaki (*right column*). *Upper row*, all persons in LSS sample; *intermediate row*, all leukemia deaths till 1978, *bottom row*, all cancer deaths (except leukemia) till 1978.

Preliminary estimates (Ellett et al. 1985) of kerma in free air distances 1000 m, 1500 m, 2000 m: Hiroshima, 5.3 Gy, 0.65 Gy, 0.07 Gy; Nagasaki, 10 Gy, 1.2 Gy, 0.16 Gy

Table 1. Risk coefficients of ICRP (averaged over age and sex)

Life-time mortality of cancer	Per Sievert
Leukemia	0.002
Mammary tumors	0.0025
Lung cancer	0.002
Osteosarcoma	0.0005
Thyroid tumors	0.0005
Other organs	0.005
	0.0125
Severe hereditary damage (2 generations)	0.004

neither be proved nor disproved at present, and it remains uncertain whether improved knowledge of the molecular mechanisms of cellular transformations will ever settle the question.

Basic principles of microdosimetry permit the statement that radiation effects on individual cells can have no threshold in dose and that their probability must be proportional to dose at low doses (Kellerer and Rossi 1982). This is so because energy is transferred to the cells by individual charged particles. At sufficiently low doses – fractions of one milligray for sparsely ionizing radiations and several milligray for densely ionizing radiations – only few cells are traversed by a charged particle. The dose determines then merely the number of cells affected, but not the energy deposition to these cells. Effects on autonomous cells must therefore be proportional to the number of cells affected and thus to dose. The statement remains valid even if the possible, and still largely unknown, role of various intracellular DNA-repair systems is taken into account. Somatic mutations are, therefore, produced without a threshold of dose. However, host factors, i.e., effects on the tissue level, may depend on dose in a way which can not be predicted. Their possible contribution to the progression of a transformed cell towards the growth of a tumor remains unknown.

A second statement on risk factors must be added. Although the estimates are largely based on the observation of the survivors of the atomic bombings, they are consistent with a wide range of studies from the medical application of X-rays. If the atomic bombings had not taken place, there would still be risk estimates of the same order of magnitude. It is less certain whether there would be the ICRP philosophy of linearity for radiation-induced tumors. However, this is the prevailing philosophy in radiation protection, and it has important implications.

Definition of the Effective Dose

For the consideration of risk factors, a few technical notions are required. The first concept is that of dose equivalent which equals absorbed dose of radiation multiplied

Table 2. Weight factors^a representing the contribution of each organ to the risk of hereditary damage or mortality from radiation-induced tumors

<i>i</i>		<i>w_i</i>
1	Gonads	0.25
2	Breast	0.15
3	Red bone marrow	0.12
4	Lung	0.12
5	Thyroid	0.03
6	Bone surfaces	0.03
7	Remaining organs	0.30

^a They equal the risk coefficients (see Table 1) normalized to their sum

Definition of effective dose:

$$H_{\text{eff}} = \sum_{i=1}^7 w_i H_i$$

where H_i is the mean dose equivalent to the organ i , and w_i is the weight factor for this organ

by a quality factor. The quality factor is, by convention, defined as a function of the linear energy transfer of charged particles and it accounts for the assumed biological effectiveness of a radiation at small doses. It is set equal to unity for all sparsely ionizing radiations, i.e., for γ -rays, X-rays, or electrons. Roughly speaking, it is equal to 10 for neutrons which transfer energy to the exposed material by releasing densely ionizing recoil nuclei. It is approximately 20 for α -particles which are also densely ionizing and produce thousands of ionizations while they traverse a cell nucleus. To avoid confusion, one has chosen the special name gray (Gy) for the unit J/kg when it is used with absorbed dose, while the special name sievert (Sv) is used when the unit is applied to dose equivalent.¹ There are proposals, at present, to change the values of the quality factor (ICRU 1986). This is likely to be a controversial topic in radiation protection in the years to come, and it is a question closely linked to the remaining uncertainties of risk assessment and to the lack of human data for the effects of neutrons.

When the body is exposed uniformly, the meaning of the dose or the dose equivalent is clear. When the body is exposed nonuniformly, or when certain organs only are exposed, more complicated specifications of dose are required. To provide a single quantity which can adequately express the resulting overall level of exposure, one has introduced the effective dose equivalent (ICRP 1977), which is now usually called the effective dose. It is a weighted average of all the organ doses. The weighting factor for each organ represents its fractional contribution to the total somatic and genetic risk (see Table 2). The notion may appear artificial, but it is, in fact, a

¹ The former units rad (1 rad = 0.01 Gy) and rem (1 rem = 0.01 Sv) are still widely used

natural matter, if one assumes proportionality to dose at low doses for radiation-induced tumors.

For clarification and illustration one may use an example familiar from the discussion after the reactor accident. The weighting factor for the thyroid is 0.03. If a child consumes a liter of milk contaminated with 1000 Bq of iodine-131, about half of the activity may be collected in the thyroid and it produces there a dose equivalent of roughly 3 mSv. Multiplication by the weighting factor results in an effective dose of roughly 0.1 mSv. For the purposes of radiation protection it is assumed that the exposure of the thyroid to 3 mSv causes a risk of the same magnitude as a whole body exposure of 0.1 mSv which may be caused, for example, by external γ -irradiation or by incorporation of cesium-137.

Validity of the Risk Estimates and Applicability of the Assessment System

One can ask two questions. First, how reliable are the risk coefficients? Second, how useful are they? An adequate answer to either question is outside the scope of the present survey. However, a brief summary can be given.

There has been occasion, in recent years, to doubt the validity of the risk estimates. The reason is that the dosimetry for the atomic bomb explosions has turned out to be incorrect (Loewe and Mendelsohn 1981). Some years ago it was thought that the larger part of the radiation effects in Hiroshima were due to neutrons emitted by the uranium bomb (Rossi and Kellerer 1974; Rossi and Mays 1978). In Nagasaki there were hardly any neutrons, because the plutonium bomb was surrounded by tons of conventional explosives, which shielded the emitted neutrons effectively. The revision of the dosimetry, while not finally concluded, has now led to the consensus that even in Hiroshima there were few neutrons. It was argued then, that effects earlier ascribed to neutrons must now be assigned to γ -rays, with a resulting increase of the risk estimates. However, the revised dosimetry has led to increased γ -doses in Hiroshima (Ellett et al. 1985), and this balances largely the disappearance of neutrons. Any resulting change of the risk estimates due to the revision of the Japanese dosimetry would appear to be less than a factor of 2.

A more substantial change of the risk estimates may arise if the excess rates of mammary tumors, thyroid tumors, lung tumors, and of intestinal tumors persist, and if they follow the increases of the spontaneous rates in the aging collective of exposed persons. The term relative risk model refers to such a persistence and age-dependent increase of excess tumor rates. The Japanese data appear to be in line with a relative risk model, and this appearance is underscored by the occurrence of breast cancer in recent years in a number of women who were very young girls at the time of the bombing. However, recent data on the British ankylosing spondylitis patients (Darby et al. 1985) point in the opposite direction. It is therefore indicated to reserve judgement on the applicability of the relative risk model and to continue the two important studies. Whatever the final conclusion may be, it is important to note, that present risk estimates are based on an observation period of about 30 years only and that an extension to longer times at risk could increase their values.

Are the risk estimates useful? They are hypothetical, because one can, at present, merely surmise but not prove that tumors are caused by small doses of ionizing radiations. In spite of this uncertainty, the risk estimates remain suitable for the pragmatic purposes of radiation protection. For hereditary damage and also for somatic mutations, the linear hypothesis is valid and it is therefore prudent and practicable to make a corresponding assumption also for radiation-induced tumors. The important consequence for radiation protection is, to replace the former concept of dose limits by the principle to keep radiation doses as low as reasonably achievable (ALARA).

The International Commission for Radiological Protection has attempted to formalize the ALARA principle and to develop it into a cost-benefit assessment. Some have gone to the point of assigning a monetary cost to a man sievert, which is the unit of collective dose, i.e., the sum of doses to individuals in a collective. In practice such formalistic approaches are likely to fail. The ALARA principle itself has, however, become a useful tool to reduce undesirable exposures, both in nuclear technology and in medical applications. When exposure limits are considered as ultimate ceilings, not as permissible levels, and when unnecessary exposures are avoided, average dose levels in controlled groups will stay far below the limits. This has, indeed, been achieved in nuclear industry. In medicine, similar efforts have been made, and data are now available which facilitate the optimization of diagnostic equipment and the cost-benefit assessment of diagnostic screening procedures. The controversy, in recent years, on mammography as a screening procedure exemplified the potential of the cost-benefit approach, and it has largely contributed to the reduction of the doses and to better definition of the indications for mammography. The prudent assumption of no dose threshold for somatic late effects has also helped to advance the use of modalities other than ionizing radiations.

Need for a Balanced View of Risks

The merits of the assessment system are less obvious, when it is misused, and when a philosophy is embraced which aims at total avoidance of radiation exposures or, at any rate, the complete avoidance of any “nonnatural” radiation exposure. The computation of hypothetical numbers of cancer deaths, usually in large collectives but without reference to their size, is then an effective means to generate confusion and even panic.

These problems became evident when the recent reactor accident produced contaminations in several European countries which exceeded levels legally set for the routine practice of radiation protection. Limits or derived limits were then erroneously interpreted as thresholds that separate harmless exposures from dangerous doses. On the other hand, the assumption of linearity and the risk coefficients were used to compute absolute numbers of expected cancer deaths. Even if they are formally correct, such computations can be highly misleading, when they are not related to spontaneous rates and their fluctuations due to various other factors.

For example, in a recent discussion, the claim was made that about 1000 cancer deaths would result from the collective dose of 75000 man sievert which results from the emission of $5.3 \cdot 10^{14}$ Bq of ^{14}C during the 40 years of projected operation of a

reprocessing plant. The computation of the collective dose is correct. However, the statement omits the fact that more than 99.9% of this collective dose is caused after the global dispersion of ^{14}C , and over a period of several thousand years. In fact, the computed number of deaths relates to 200 generations of all of mankind. It is therefore hardly conceivable how the number 1000 could be meaningful.

Computations of assumed numbers of cancer deaths may be less widely removed from reality when applied to the consequences of large-scale radioactive contaminations from the reactor catastrophe. But they are grossly misleading when employed to induce personal anxieties. Possible increases of tumor rates in Western Europe are far smaller than the existing rates and than their fluctuations due to various controllable and uncontrollable factors. The absence of a personal threat is due to the dilution of the risk within a population of many millions. On the other hand, such dilution is no reason to disregard the possible detriments and to omit suitable measures. It is essential to distinguish between a tangible personal threat and an undesirable addition to the pool of existing detriments. To neglect risks to large populations, unless they break through the threshold of epidemiological ascertainment, would be a fatal counterposition against unfounded anxieties. Reasonable administrative measures to reduce doses, for example, from iodine-131 in milk, were therefore justified and were in line with the ALARA principle.

A more balanced view of risks and their numerical values is required. Further efforts will be needed to achieve such a view, and to have it take the place of prevailing misconceptions and collective anxieties.

References

- Chmelevsky D, Kellerer AM, Spiess H, Mays CW (1986) A proportional hazards analysis of bone sarcoma rates in German ^{244}Ra radium patients. In: Gössner W et al (eds) *The radiobiology of radium and thorotrast*. Urban and Schwarzenberg, München, pp 32–37
- Court Brown WM, Doll R (1956) The hazards to man of nuclear and allied radiations. Report of the Medical Research Council (Br) Appendix B, p 87. Her Majesty's Stationery Office, London
- Darby SC, Nakashima E, Kato H (1985) A parallel analysis of cancer mortality among atomic bomb survivors and patients with ankylosing spondylitis given X-ray therapy. *JNCI* 75: 1–21
- Ellett WH, Christy RF, Lowder WM (1985) A new dosimetry for a-bomb survivors. *Radiat Prot Dosimetry* 13: 311–318
- Failla G (1932) Radium protection. *Radiology* 19: 12–21
- Frieben A (1902) Demonstration eines Cancroids des rechten Handrückens, das sich nach langdauernder Einwirkung von Röntgenstrahlen entwickelt hatte. *Fortschr Geb Röntgenstr* 6: 106
- ICRP (1977) *Annals of the ICRP, Publication 26. Recommendations of the International Commission on Radiological Protection*. Pergamon, Oxford New York Frankfurt
- ICRU Report 40 (1986) *The quality factor in radiation protection*. International Commission on Radiation Units and Measurements. Bethesda, Md
- Kellerer AM, Rossi HH (1982) Biophysical aspects of radiation carcinogenesis. In: Becker FF (ed) *Cancer, a comprehensive treatise*. vol 1, 2nd edn. Plenum, New York, pp 569–616
- Lewis EB (1957) Leukemia and ionizing radiation. *Science* 125: 965–972
- Lewis EB (1963) Leukemia, multiple myeloma, and aplastic anemia in American radiologists. *Science* 142: 1492–1494
- Loewe WE, Mendelsohn E (1981) Revised dose estimates for Hiroshima and Nagasaki. *Health Phys* 41: 663–666
- Mays CW, Spiess H, Chmelevsky D, Kellerer AM (1986) Bone sarcoma cumulative tumor rates in patients injected with ^{224}Ra . In: Gössner W et al (eds) *The radiobiology of radium and thorotrast*. Urban and Schwarzenberg, München, pp 27–31

- Muller HJ (1927) Artificial transmutation of the gene. *Science* 66:84–87
- National Academy of Sciences, National Research Council (1980) The effects on populations of exposure to low levels of ionizing radiation. Washington, D.C.
- Rossi HH, Kellerer AM (1974) The validity of risk estimates of leukemia incidence based on Japanese data. *Radiat Res* 58:131–140
- Rossi HH, Mays CW (1978) Leukemia risk from neutrons. *Health Phys* 34:353–360
- Rundo J, Keane AT, Lucas HF, Schlenker RA, Stebbings JH, Stehney AF (1986) Current (1984) status of the study of ^{226}Ra and ^{228}Ra in humans at the Center for Human Radiobiology. In: Gössner W et al (eds) *The radiobiology of radium and thorotrast*. Urban and Schwarzenberg, München, pp 14–21
- Smith PG, Doll R (1982) Mortality among patients with ankylosing spondylitis after a single course of treatment with X-rays. *Br Med J* 284:449–460
- UNSCEAR Report (1977) Sources and effects of ionizing radiation. United Nations, General Assembly, 32nd Session, Supplement No 40 (A/32/40) UN, NY
- van Kaick G, Muth H, Kaul A, Wesch H, Immich H, Liebermann D, Lorenz D, Lorenz WJ, Lührs H, Scheer KE, Wagner G, Wegener K (1986) Report on the German thorotrast study. In: Gössner W et al (eds) *The radiobiology of radium and thorotrast*. Urban and Schwarzenberg, München, pp 114–118
- von Jagie N, Schwarz G, von Siebenrock L (1911) Blutbefunde bei Röntgenologen. *Berl Klin Wochenschr* 48:1220–1222
- Wick RR, Chmelevsky D, Gössner W (1986) ^{224}Ra : risk to bone and haematopoietic tissue in ankylosing spondylitis patients. In: Gössner W et al (eds) *The radiobiology of radium and thorotrast*. Urban and Schwarzenberg, München, pp 38–44
- Yoshimoto Y, Kellerer AM, Rossi HH, Nakashima E, Kato H (1981) Coordinate plots depicting basic data on members of the life span study sample. Radiation Effects Research Foundation, Research Protocol, RERF RP 10-81, 1–3

Subject Index

- across-species differences 81
- actinic cheilitis 137
 - keratoses 137
- activation, metabolic 88
- acute toxicity 70
- African, black 138
- AIDS 171, 184
- ALARA principle 151
- albinism 140
- alcohol consumption 191
- aldrin epoxidase 134
- Ames test 36
- animal carcinogenesis 31, 80
 - experiments 87
- ankylosing spondylitis 144, 145, 150
- antenatal diagnosis 9
- antioxidants 92
- antismoking programs 128
- antitobacco propaganda 120
- artificial light sources 138
- asbestos 28
- ataxia-telangiectasia (AT) 6, 24
- atomic bomb 168
 - survivors 145
- avoidance of exposure 89

- background radiation 17
- basal cell carcinoma 137
- basophilic degeneration 137
- benz[a]anthracene 34
- benzo[a]pyrene 94
- bioassay 32, 58, 80, 82
- biological end-points 33
 - markers 99
- biomonitoring 32, 133
- bis(-chloromethyl)ether 28
- bladder carcinoma 76
- blood group 8
- breast cancer 150
- bromodeoxyuridine (BrdUrd) 40
- Burkitt's lymphoma 173, 190

- cancer, causes 66
 - , –, nutritional 66
 - of the bladder 76
 - of the breast 150
 - , carbohydrate metabolism and 52
 - , cervical 172, 176, 190
 - epidemiology 95
 - families 8
 - , gastric 21
 - induction, monocausal 90
 - , occupational 27, 28
 - registries 20
 - of the scrotum 94
 - susceptibility 8
- carcinogenesis, chemical 27, 87
- carcinogenic risk 78, 81
- carcinogenicity 33
- carcinogens, occupational 30
- case-cluster 20
- cell-cell interaction 82
- cellular heterogeneity 50
- Celtic type 138
- cervical cancer 18, 191
- chemical carcinogenesis 27, 87
 - , primary prevention of 87
 - , theory of 88
 - hazards 20
 - substances, classification 80
- chemoprevention 92
- Chernobyl accident 167, 168
- childhood leukemia 17
- chlorodinitrobenzene (CDNB) 37
- cholangiofibrosis 54
- chromosomal abnormalities 7
- chromosome breakage syndromes 6
 - deletion 5
 - rearrangements 6
- chronic lung disease 133
- cigarettes 117, 121, 124
 - , average tar content 118
 - , filter 116
 - , less harmful 192
 - , low yielding 116
- cigarette smoking 114, 128, 130
 - tar 14
- classification of chemical substances 30, 80
 - systems 28, 29

- cocultivation experiments 82
- continuous cell lines 34
- Cotinine, elimination in active *vs* passive smokers 110
 - as biological marker of exposure to tobacco 109, 110
- cytochrome P448 34
 - P450 34

- deposition densities 160
- detection, early 11
- detoxifying processes 90
- dexamethasone 34
- diagnostic criteria 75
- dial painters 144
- displasias 190
- DNA-adducts with tobacco-specific nitrosamines 108, 109
 - amplification 171
- DNA damage 33
 - polymorphisms 9
 - probes 9
 - repair 40, 148
 - process 91
- dose 154
 - , collective 151, 152
 - dependence of hepatic preneoplasia 56
 - , effective 148, 162
 - equivalent 148, 157
 - response relationships 80, 96
 - , virtually safe 73
- Down's syndrome 7

- effective dose 148, 162
- elastosis 137
- electrons 149
- environmental carcinogenesis 95, 96
 - , multicausal 90
- enzyme-altered foci 56
 - modulators 91
- epidemiologic surveillance 98
- epidemiology 24, 31, 71, 87, 133
- Epstein-Barr Virus (EBV) 172, 173, 182, 190
- ethoxyresorufin-O-deethylase 34
- eumelanin 138
- exposure 80
 - , avoidance 89
 - , reduction 89
- extrapolation 81

- filter cigarettes 116
- flavones 91
- foci 47, 56
 - , acidophilic cell 49
 - of altered hepatocytes 50, 56, 58
 - , basophilic 51
 - , clear cell 49
 - , enzyme-altered 56
 - , glycogen storage- 51
 - , mixed cell 51
 - , preneoplastic 53, 58
 - , regression of – 57
- gastric cancer 21
- gene mutation 5
- genetic/environmental interactions 3, 4
 - counselling 11
 - predisposition 3
 - screening 10
 - strategies 9
 - susceptibility 14
- glass fibers 133
- glucuronosyltransferase 34
- glutathione 37
- glutathione-S transferase 37
- glycogenesis 50
- glycogen storage foci 51
- gonadal dysgenesis 8
- gray (Gy) 149

- “hazard” 81
 - assessment 31, 66
- HBV (see hepatitis B virus)
- health education 118, 126, 192
 - passport 127, 128
- hepatic neoplasia, dose-dependence 56
 - preneoplasia 48
 - , dose-dependence 56
- hepatitis B 181, 183
 - immunoglobulin (HBIG) 185
 - vaccine 186
 - virus 17, 171–173, 191
 - DNA 184
 - vaccine 184–187
- hepatocarcinogenesis 50
 - , models of 54
- hepatocellular carcinoma (HCC) 17, 172, 183, 184, 191
- hepatoma lines 39
- herpes virus 181
- high-risk groups 11
- HLA 9
- hormones 20
- hormone balance 7
- human carcinogenesis 80, 82
- hydrogen peroxide 42
- hydroxylase enzymes 6

- IARC 28, 81
 - list 28
- immune deficiency syndromes 7
 - response 7

- immunization 18, 182
 industrial hygiene 98
 initiation, tumor 88
 initiation-promotion protocol 55
 interferon 181
 intervention studies 133
 iodine-131 150
 ionizing radiations 16, 87, 143, 166, 167
- keratoacanthoma 137
α-ketoacids 42
 kidney 54
- latency period 190
 latent tumor cell 88
 LAV/HTLV III (HIV) 181
 legal and administrative approaches 98
 – measures 89
 lentigo maligna 137
 leukemia 24, 143, 147, 148
 –, childhood 17
 lifestyle 10
 light-blocking agents 166
 light-exposed skin areas 139
 light habituation 141
 light-induced callus 141
 lip cancer 137
 liver lesions, focal 56
 –, preneoplastic focal 58
 liver-specific-functions 39
 – tumors 145
 longevity 75
 low-yield cigarettes 116
 lung cancer 114, 115, 117, 130, 148, 167, 175
- MAK values 81
 malignant melanoma 137
 mammary tumors 76, 148
 mammography 151
 "markers" of chemical exposure 99
 mathematical models 31, 73
 maximum tolerated doses 70
 Mediterranean type 138
 melanomas 18
 Mendelian inheritance 7
 metabolic activation 33, 38, 88
 microdosimetry 148
 modified production techniques 89
 monocausal cancer induction 90
 monoclonal tumors 190
 monooxygenases 34
 mouse hepatitis virus 191
 multicausal environmental carcinogenesis 90
 mutagenic effects 87
 mutagenicity 33
 mutations 147, 148
- β*-naphthylamine 94
 neoplastic hepatic nodules 50, 53
 neurological disorders 133
 neutrons 149, 150
 nicotine 118, 120, 121
 – as a biological marker of exposure to tobacco 109, 110
 – as a precursor to carcinogens 105, 108
 –, in the particular phase of smoke 100
 –, in the vapor phase of smoke 110
 nitrates 21
 nitrosamines (see also tobacco-specific nitrosamines) 193
 – as human carcinogens 111
 –, estimated human exposure 107
 nucleophilic sulfur-containing compounds 91
- occupational cancer 27, 28, 97
 – carcinogens 30
 – etiology of cancer 96
 – exposure 96
 oncogene expression 190
 oncogenic viruses 87, 181
 organ-specificity 82
 osteosarcomas 144, 145, 148
- papillomavirus 171–178
 papovavirus 181, 183, 190
α-particles 149
 parvoviruses 171
 peer groups 192
 personal measures 89
 – protective equipment 98
 pharmacokinetics 80
 phenobarbital 34
 pheomelanin 138
 photo-augmentation 138
 polycyclic enzymes 6
 polyposis coli 11
 population screening 10
 potency 68, 82
 predictivity figures 68
 pregnenolone-16-*α*-carbonitrile 34
 premarket screening 98
 – toxicologic screening 97
 preneoplastic focal lesions 47, 48, 53–59
 prevention 14, 65
 –, primary 87
 –, secondary 97
 –, tertiary 97
 preventive oncology 130
 primary hepatocyte cultures 33
 progression 7
 proto-oncogene 9
 public intervention campaigns 121

- radiation, background 17
- , ionizing 87, 143
- , ultraviolet 137
- radionuclides 144
- radium-224 144
- radium-226 144
- radon 167
- “radon-daughter-exposure” 155
- rat liver foci bioassay 54, 58
- γ-rays 149, 150
- reactive carcinogens, scavenging of 90
 - oxygen species 34
- reactor accident 151
- rearrangement of genes 24
- reduction of exposure 89
- regression of lesions 82
 - of foci of altered hepatocytes 57
- regulations 80
- relative risk models 150
- repair 83
- reproducibility 81
- restriction of use 81
- retinoblastoma 5
- retinoids 92
- retroviruses 182, 183
 - , reverse transcriptase 181
- risk 14, 81
 - assessment 59
 - , coefficients 145, 148, 150, 155
 - evaluation 31
 - management 66
- Rn-concentration (EEC_{Rn}) 157
- rodent liver cancer 76

- S9 fraction 33
- scavenging of reactive carcinogens 90
- screening 11
 - , genetic 10
 - , population 10
- secondary prevention 97
- self-help programs 122
- serum banks 21
- short-term tests 33, 81, 87
- sievert (Sv) 149
- skin cancer 137
 - tanners 139
- skin-tanning agents 141
- smoke cessation 124
 - programs 133
 - techniques 124
- smokers 167
- smoking, association with cancer 101, 178
 - , cessation of 104, 118, 125, 126
 - habits 118
 - , nicotine delivery to nervous system 120
 - , relationship to lung cancer 115
 - rooms 93
- snuff, carcinogenicity of 101
- snuff-dipping 101, 107
- solariums 139
- squamous neoplasms 76
- stop experiments 57
- substitution 98
- sulfotransferases 37
- sunbathing 140
- sunlight 166
- sunscreens 139

- tanning 139
- target organs 68
- TD50 68
- terrestrial sunlight 138
- tertiary prevention 97
- thiourea 40
- thorium-232 145
- thorotrast 144, 145
- threshold 143, 147, 148, 151
- thyroid 150
 - tumors 148
- tobacco 14, 114, 115
 - chewing 129
 - smoke, aromatic amines 104, 105
 - , bioassays of 101, 102
 - , cocarcinogens in 102
 - , organ-specific carcinogens in 104, 105
 - , nitrosamines in (see tobacco-specific nitrosamines)
 - , particular matter of 101, 102, 105
 - , polynuclear aromatic hydrocarbons in 102, 103
 - , reduction of carcinogenicity 102, 103
 - , tumorigenic potential of 103
 - , tumor initiator in 102
 - , promoters in 102
 - , vapor phase of 105
 - smoking 119, 122
- tobacco-specific nitrosamines
 - , biochemistry of 108
 - , carcinogenicity of 106
 - , DNA adducts of 108, 109
 - , endogenous formation of 110
 - , formation in tobacco and tobacco smoke 105
 - , levels in commercial tobacco products 107
- translocation of myc gene 190
- tumor cell, latent 88
 - initiation 88
 - rates 152
- tumors, liver 145
 - , mammary 148
 - , thyroid 148

- ultraviolet A 138
 - B 138
 - C 138
 - radiation 137, 166
- "unscheduled DNA synthesis" (UDS) 40
- uranium miners 167
- urothelium 54
- UV-blocking creams 166

- ventilation 98
- vinyl chloride 28
- virus, EBV 171-173, 182, 190
 - , HIV 181, 183
 - , hepatitis B virus 171-173, 181, 183
 - , herpes 171, 181
 - , HTLV I 171, 173, 182
 - , HTLV II 182
 - , HTLV III (HIV) 182
 - , hybrid 182
 - , LAV/HTLV III 181
 - , oncogenic 87, 171-178, 181
 - , papilloma 171-178
 - , papova 181, 183, 190
 - , retrovirus 181
- vitamin A 92

- World Health Organization (WHO) 186

- xenobiotics 34
- xeroderma pigmentosum 24, 140
- X-rays 143, 145, 149

Bayerische
Staatsbibliothek
München